Search research articles
Contact Us
Filters
Showing results (171-180 of 186) with videos related to
Page
of 19
Sort By:
Prostate Cancer and Prostatic Diseases
|
December 9, 2025
Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer
Udit Singhal, Ralph Jiang, James A Proudfoot, et al.
JAMA Oncology
|
March 28, 2020
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial
Ryan Phillips, William Yue Shi, Matthew Deek, et al.
Journal of the National Cancer Institute
|
September 2, 2022
Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease
Shivanshu Awasthi, G Daniel Grass, Javier Torres-Roca, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
A Prospective Validation of the Decipher Genomic Classifier in Men With Early Localized Prostate Cancer: The VANDAAM Study
Kosj Yamoah, Purvish Trivedi, Shivanshu Awasthi, et al.
BMC Cancer
|
June 4, 2020
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
Hamza Hasan, Matthew P Deek, Ryan Phillips, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
Phuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2025
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
Jarey H Wang, Alexander D Sherry, Soha Bazyar, et al.
European Urology
|
April 18, 2019
Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis
Kiri A Sandler, Ryan R Cook, Jay P Ciezki, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 7, 2018
Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study
Kiri A Sandler, Ryan R Cook, Jay P Ciezki, et al.
JAMA Oncology
|
October 22, 2020
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate
Robert T Dess, Krithika Suresh, Michael J Zelefsky, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 186) with videos related to
Sort By:
Page
of 19
Prostate Cancer and Prostatic Diseases
|
December 9, 2025
Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer
Udit Singhal, Ralph Jiang, James A Proudfoot, et al.
JAMA Oncology
|
March 28, 2020
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial
Ryan Phillips, William Yue Shi, Matthew Deek, et al.
Journal of the National Cancer Institute
|
September 2, 2022
Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease
Shivanshu Awasthi, G Daniel Grass, Javier Torres-Roca, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 11, 2026
A Prospective Validation of the Decipher Genomic Classifier in Men With Early Localized Prostate Cancer: The VANDAAM Study
Kosj Yamoah, Purvish Trivedi, Shivanshu Awasthi, et al.
BMC Cancer
|
June 4, 2020
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
Hamza Hasan, Matthew P Deek, Ryan Phillips, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2022
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
Phuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2025
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
Jarey H Wang, Alexander D Sherry, Soha Bazyar, et al.
European Urology
|
April 18, 2019
Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis
Kiri A Sandler, Ryan R Cook, Jay P Ciezki, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 7, 2018
Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study
Kiri A Sandler, Ryan R Cook, Jay P Ciezki, et al.
JAMA Oncology
|
October 22, 2020
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate
Robert T Dess, Krithika Suresh, Michael J Zelefsky, et al.
Page
of 19